munoassays. Results: Copeptin correlated in the entire study population more strongly with umbilical artery base excess than S100B and erythropoietin, and only copeptin correlated with arterial pH. Furthermore, only copeptin levels were significantly higher in cases of birth asphyxia, and in vaginally born neonates they were found to increase as a function of labor duration. Copeptin was elevated in neonates born via vacuum extraction, whereas erythropoietin levels showed a slight increase after emergency cesarean section. Conclusions: In this study population, S100B and erythropoietin were not valid biomarkers of birth asphyxia. In contrast, our work suggests that copeptin has high potential to become a routinely used biomarker for acute birth asphyxia and neonatal distress.
pairments in individuals who develop neonatal hypoxicischemic encephalopathy (HIE) range from minor cognitive problems and sensorimotor defects to cerebral palsy [1, 2] . Finding methods for identifying those neonates who would benefit from neuroprotective treatments such as therapeutic hypothermia is a major challenge because of the restricted time window of only a few hours for decision making. The increasing risk of HIE associated with enhanced acidemia has been well established. The Apgar scores at 5 min are known to correlate with the risk of neurological disability [3] . However, the sensitivity and specificity of arterial cord blood pH values and Apgar scores with regard to outcome following HIE are low [2] . Thus, reliable biomarkers for predicting outcome after birth asphyxia are urgently needed.
A number of studies on blood-borne protein biomarkers in neonates have been published in recent years [4] [5] [6] . Among these, erythropoietin (EPO) is a biomarker of chronic hypoxia [7] , and high levels of umbilical plasma EPO at birth are associated with an increased risk for adverse outcome [8] . S100B is considered as a biomarker of brain cell damage [9] , and its levels are known to rise at the early phase of acute asphyxia [6] . In the present study, we examine the utility of cord serum copeptin, a byproduct of arginine vasopressin (AVP) release, as a biomarker of birth asphyxia based on a comparison with EPO and S100B. The rationale of this approach lies in the fact that a massive surge of AVP release takes place during normal vaginal birth in response to activation of the fetal hypothalamic-pituitary-adrenal (HPA) axis, which is further accentuated by various kinds of stress factors such as infections, intrauterine growth restriction, and acidosis/birth asphyxia [4, 5, 10, 11] . In contrast to AVP, copeptin is biochemically stable with a much longer half-life, and it is released in an equimolar ratio to AVP, making it an ideal surrogate for AVP measurements [11, 12] . One of the practical advantages of copeptin is that it is widely used as a biomarker of various pathophysiological states like lower respiratory tract infections, septic shock, and stroke in emergency departments [13] .
Methods

Study Design and Patients
The serum samples for this retrospective study were collected in the Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland, between May 2012 and April 2013. The study, approved by the local Ethics Committee of the Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland (105/13/13/03/2012), consisted of 151 singleton births at or beyond 37 +0 gestational weeks. Umbilical artery blood samples were collected immediately after birth from 72 neonates with suspected asphyxia, based on a 1-min Apgar score <4. The 1-min Apgar score was used only for patient recruitment, to allow midwives to identify neonates suspected of having suffered from birth asphyxia. Umbilical artery cord blood samples from 79 control neonates with a 1-min Apgar score ≥ 4 were collected during the 5-day work week. Pregnancies complicated by maternal type 1 diabetes ( n = 1), preeclampsia ( n = 3), fetal growth restriction ( n = 4), and Rh immunization ( n = 1) were excluded. In addition, 1 neonate was excluded because of chromosomal anomaly and 1 had mitochondrial disease, leaving a total of 140 neonates for the final analysis. The neonates were divided into 2 groups, asphyxia and control, for data analysis. The neonate was considered to fulfill the diagnostic criteria for birth asphyxia if 2 of 3 criteria were met: umbilical artery pH <7.1, umbilical artery base excess (BE) ≤ 12 mmol/L, and a 5-min Apgar score <7 [14, 15] .
Gestational age was defined by fetal crown-rump length measurement at the first-trimester ultrasound screening. Deliveries were all planned vaginal. Indications for emergency cesarean sections (ECS) were fetal distress ( n = 29), labor dystocia ( n = 10), prolonged second stage of delivery ( n = 2), chorioamnionitis ( n = 1), fetal malpresentation ( n = 3), unsuccessful vacuum extraction ( n = 4), and umbilical cord prolapse ( n = 2). Data on maternal pregnancy characteristics and short-term perinatal outcome were collected from the hospital charts ( Table 1 ) . Birth weight z-score was defined according to the Finnish population standardized for sex and gestational age [16] .
Blood samples from the umbilical artery were used for measurements of pH, BE, pO 2 , and pCO 2 (ABL800 Flex blood gas analyzer; Radiometer, Copenhagen, Denmark). Serum samples from the umbilical artery were used for biomarker measurements.
Copeptin Measurements
We used a sandwich enzyme-linked immunosorbent assay (ELISA; for methodological details see the online suppl. material; see www.karger.com/doi/10.1159/000456063 for all online suppl. material). The interassay variability was 5.8%, which was estimated by calculating the coefficient of variation (CV) from 8 duplicate samples run on 2 plates on 2 separate days. Fifteen serum samples were analyzed with both the ELISA and the BRAHMS copeptin Kryptor assay used in previous publications [4, 5] , and a highly significant linear correlation was found (Pearson r = 0.9793, p < 0.0001), covering the full range of values obtained using the Kryptor: 6.0-4,637 pmol/L (median 381.2 pmol/L). This excellent linear correlation, with an R 2 of 0.9591 indicating a congruence of 96% between the 2 methods, was used to convert the copeptin concentrations obtained with the ELISA to Kryptor concentrations. This allows for a direct comparison of our data with the already published copeptin results in neonates.
S100B Measurements
Serum S100B was measured with an electrochemiluminometric immunoassay using Modular e170 analyzer (Roche Diagnostics). The detection range for the S100B assay was 0.005 μg/L and functional sensitivity was <0.02 μg/L. The intra-assay CV was <2.1%, and the interassay variation was >6.4%. 
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EPO Measurements
EPO was measured with a solid-phase chemiluminescent enzyme immunometric assay using Immulite 2000 XPI analyzer (Siemens Healthcare Diagnostics). The intra-assay CV was 3.6-6.8%, while the total CV was 6.4-10.3%. The detection limit was 1.0 IU/L, and functional sensitivity (CV 20%) was 1.5 IU/L.
Statistical Analysis
All 3 biomarkers were measured from each of the 140 samples included in this study. The following statistical analyses were performed with GraphPad Prism 6 or SPSS 22. Prior to calculating correlations and significances, statistical outliers ( p < 0.01) for copeptin and S100B ( n = 1 for each) were excluded from the study population. Correlations between the pH, BE, S100B, EPO, and copeptin values from all remaining samples were calculated with the Spearman correlation coefficient. Copeptin, S100B, and EPO values between the study groups were compared using the MannWhitney U test or the Kruskal-Wallis test, and a receiver operating characteristic (ROC) curve was drawn to determine the diagnostic accuracy of copeptin to birth asphyxia. The χ 2 test or Fisher exact test was used to determine significant differences in the study population.
Results
Maternal and Fetal/Delivery Characteristics
The maternal and fetal/delivery characteristics are shown in Table 1 . There were no statistically significant differences in any of the maternal or delivery characteristics between the 2 study groups.
Dependence of Biomarker Levels on Umbilical Artery pH and BE
The median pH, BE, pO 2 , and pCO 2 values of the neonates, which are routinely measured from umbilical arterial cord blood at birth, are shown in Table 1 . The dependence of the 3 biomarkers on the blood acid-base parameters is given in Figure 1 . Only copeptin levels showed a significant correlation with umbilical artery pH ( r = -0.6219, p < 0.0001; Fig. 1 a) . All 3 biomarkers correlated with umbilical artery BE ( Fig. 1 d-f) , with copeptin showing by far the highest correlation coefficient ( r = -0.6372, p < 0.0001). Biomarker Levels and Asphyxia Twenty-seven neonates in the study population belonged to the birth asphyxia group (see Methods for present criteria). Copeptin levels were significantly higher among the neonates in the birth asphyxia group compared to unaffected controls (mean 2,450 vs. 1,226 pmol/L, p < 0.0001; Fig. 2 c) , whereas no differences in S100B ( Fig. 2 a) or EPO ( Fig. 2 b) levels were found. ROC curve analysis showed that copeptin concentrations discriminated with moderate accuracy between asphyxia, as defined in this study, and controls: the area under the curve was 0.76 (95% CI 0.69-0.86; Fig. 2 d) . A cutoff of 1,522 pmol/L had a sensitivity of 77% and a specificity of 70%.
Biomarker Levels and Delivery Mode
All 140 deliveries were planned vaginal, but 51 neonates were ultimately born by ECS. Of the 89 vaginal deliveries, 33 were assisted with vacuum extraction. There were no differences in the delivery mode between the asphyxia and control study groups ( Table 1 ) . Copeptin levels were higher among the neonates born via vacuum extraction compared to ECS (mean 2,021 vs. 1,190 pmol/L, p = 0.003; Fig. 3 a) or normal vaginal delivery, although the latter difference did not reach statistical significance (mean 2,021 vs. 1,362 pmol/L, p = 0.0522; Fig. 3 a) . No differences in S100B levels were found between the groups ( Fig. 3 b) , whereas EPO levels were higher among neonates born via ECS compared to normal vaginal delivery or vacuum extraction (means 713.7, 78.41, and 61.15 U/L, respectively; p = 0.0002 and p = 0.001; Fig. 3 c) , which might reflect prenatal conditions [7] .
Biomarker Levels in Relation to
Other Variables S100B levels were higher in male neonates ( p = 0.0378), but copeptin and EPO levels did not differ based on the sex of the neonate. All biomarkers showed a correlation with the 5-min Apgar score, and copeptin and S100B correlated also with the 10-min Apgar score ( Table 2 ). Copeptin and S100B levels did not correlate with gestational age at birth, whereas EPO levels did ( r = 0.4513, p < 0.0001). Only copeptin levels correlated significantly with birth weight ( r = -0.1713, p = 0.0438). Among the 89 neonates born vaginally, copeptin levels increased as a function of the total duration of labor ( r = 0.3267, p = 0.0019) and the duration of the second stage of labor ( r = 0.2787, p = 0.0086; Table 2 ). EPO and S100B levels did not correlate with either of these variables. 
Discussion
A wide spectrum of adaptive processes in respiratory, cardiovascular, and metabolic functions are triggered at birth [4, 10] . Changes in biomarker concentrations during birth reflect, at least in part, physiological fetal adaptive reactions, such as enhanced activation of the HPA axis (see below), in response to normal or complicated delivery. Distinct biomarkers have different profiles during fetal and neonatal asphyxia [4, 7, 17, 18] . The S100B level in plasma has been shown to rise at the early phase of acute asphyxia [6, 18] , and significantly higher S100B levels have been reported in asphyxiated term neonates with intraventricular hemorrhage (IVH) or HIE compared to asphyxiated neonates without IVH/HIE or apparently healthy neonates [19] . EPO is a biomarker of Comparisons between the birth asphyxia and control groups. There were no significant differences in S100B ( a ) or EPO ( b ) levels between the groups. Copeptin levels ( c ) were significantly higher in the asphyxia group compared to the control group. The medians and p values of the Mann-Whitney U test are shown ( a-c ). d ROC curve for cord serum copeptin concentrations in relation to birth asphyxia. The dashed lines indicate the optimal discriminative cutoff of 1,522 pmol/L, resulting in a sensitivity of 77% and a specificity of 70%. Comparisons between biomarkers and delivery mode. Copeptin levels ( a ) were significantly higher in neonates born via vacuum extraction compared to emergency cesarean section, whereas no differences in S100B levels ( b ) were found between groups.
EPO levels ( c ) were significantly higher in neonates born via emergency cesarean section compared to the other 2 groups. The medians are shown in each panel, and p values of the Kruskal-Wallis test are shown when the difference was significant.
chronic hypoxia, and increased levels can be detected in fetal plasma and amniotic fluid in various pathological pregnancies [7] . An association of high EPO levels during pregnancy and adverse acute neonatal outcome -such as decreased umbilical cord pH, pO 2 , and BE, and increased intensive care unit admission -has also been reported [7, 20] . Furthermore, high levels of umbilical plasma EPO at birth are associated with an increased risk for death or abnormal neurological outcome at 2 years of age [8] .
There are many a priori reasons why copeptin might turn out to be a highly useful biomarker of birth asphyxia, and a number of previous observations point in this direction [4, 5, 21] . During birth, the HPA axis shows massive activation, which results in the release of AVP, and this response is further enhanced by various types of stressors. Since AVP is highly unstable with a short half-life of 4-20 min [22] , assays of this hypothalamic hormone itself are not suitable for clinical use. However, AVP is derived from a larger precursor peptide which contains copeptin, a stable C-terminal fragment with 39 amino acids. Copeptin is released in an equimolar ratio to AVP [23] . In line with the underlying HPA-based mechanisms, copeptin levels in cord blood increase in different stress situations, such as infections and hypoxia, both in term and preterm pregnancies [4, 5, 21] . High copeptin levels at birth are related to acute adverse neonatal outcomes such as IVH [21] .
The single most important criterion for diagnosis of birth asphyxia is profound metabolic acidosis [14, 15] . Notably, copeptin levels increase along with decreasing umbilical cord blood pH and BE during normal birth [4] , and they are even higher following birth asphyxia [5] . This means that the dynamics of enhanced copeptin plasma concentrations cover a wide range of levels of acidemia from normal to severely abnormal, i.e., those prevailing in birth asphyxia.
In line with the above considerations and data, we demonstrate here that copeptin levels are highly correlated with both arterial cord blood pH and BE ( Fig. 1 ) . The strong and highly significant dependence of high copeptin levels on negative BE shown presently is of particular interest. In excellent agreement with the above data, copeptin levels turned out to be significantly higher in asphyxiated neonates versus controls in the present study. The sensitivity and specificity parameters in the ROC analysis were not as high as previously shown [5] , which is attributable to the present inclusion criteria of the control group based on a 1-min Apgar score ≥ 4. In contrast, no difference was seen in S100B and EPO levels ( Fig. 2 ) , most likely because of the relatively mild asphyxia criteria in the present work.
A further important finding in the present study is that copeptin levels increased as a function of the total duration of labor and on the duration of the second stage of labor, while EPO and S100B levels did not correlate with either variable. This result with copeptin is most likely explained by very recent observations that just a few contractions (most likely acting via transient periods of minor hypoxia on the fetus) are sufficient to trigger detectable AVP/copeptin [24] . Given the cumulative nature of the copeptin levels with a half-life of 30 min [25] , the above dependence on labor duration is readily explained. Thus, future work on sequential measurements of copeptin may turn out to be valuable in enhancing the prognostic power of this biomarker.
It has been previously shown that significantly higher copeptin concentrations are observed after vaginal delivery compared to delivery by primary cesarean section [4] . In the present study, the patient cohort included only neonates born by ECS preceded by periods of labor contractions with variable duration. Thus, it is not surprising that 66 no significant difference in copeptin levels was observed between neonates born vaginally or via ECS. However, copeptin levels were higher after vaginal delivery assisted by vacuum extraction compared to those after ECS or normal vaginal delivery, as previously reported [4] . To summarize, our study indicates that copeptin has a high potential to become a routine biomarker for neonatal distress and asphyxia. From a (patho)physiological point of view, its advantages are based on the key role of AVP in the adaptations of the fetus to birth. From a practical point of view, it is of much importance that serum copeptin is widely used as a biomarker in adults in emergency departments [13] , and therefore this approach can be readily extended to neonatal intensive care units. Future studies are needed to determine whether copeptin concentrations at birth correlate with the severity of HIE and, more importantly, with long-term neurological outcome following birth asphyxia.
